Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease

N Karin1, O Binah, N Grabie

  • 1Department of Neurology and Neurological Sciences, Beckman Center for Molecular and Genetic Medicine-B002, Stanford University School of Medicine, CA 94305, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|May 20, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Evidence of Solar Neutrino Interactions on ^{13}C.

Physical review letters·2026
Same author

Measurement of Reactor Antineutrino Oscillation at SNO.

Physical review letters·2025
Same author

Evidence of Antineutrinos from Distant Reactors Using Pure Water at SNO.

Physical review letters·2023
Same author

Genome-Wide Association Study and Post-genome-Wide Association Study Analysis for Spike Fertility and Yield Related Traits in Bread Wheat.

Frontiers in plant science·2022
Same author

Impact of incarceration on nutritional status and oral health among male inmates of central jail of Jaipur city, India.

Revista espanola de sanidad penitenciaria·2020
Same author

A cross-sectional study to assess the prevalence of early childhood caries and associated risk factors in preschool children in district Mandi, Himachal Pradesh.

Journal of the Indian Society of Pedodontics and Preventive Dentistry·2019

Shortened myelin basic protein peptides effectively treat autoimmune diseases like multiple sclerosis by acting as tolerogens. These non-antigenic peptides reverse paralysis and anergize autoreactive T cells, offering therapeutic potential.

Area of Science:

  • Neuroimmunology
  • Autoimmune disease research
  • Peptide therapeutics

Background:

  • Myelin basic protein (MBP) p87-99 is an immunodominant epitope targeted by T cells in multiple sclerosis (MS) lesions.
  • This MBP peptide can induce experimental autoimmune encephalomyelitis (EAE), a model for MS.

Purpose of the Study:

  • To design non-antigenic truncated peptides based on the pathogenic MBP p87-99 epitope.
  • To evaluate the therapeutic potential of these truncated peptides in autoimmune disease models.

Main Methods:

  • Design and synthesis of truncated peptides derived from MBP p87-99.
  • In vivo assessment of peptide antigenicity and immunomodulatory effects (IFN-gamma, TNF-alpha production).
  • Evaluation of therapeutic efficacy in a rat model of EAE (paralysis reversal).

Related Experiment Videos

Main Results:

  • Truncated peptides were non-antigenic but reduced pro-inflammatory cytokine production (IFN-gamma, TNF-alpha).
  • A 7-mer truncated peptide (FKNIVTP) completely reversed paralysis in EAE rats within 24 hours.
  • These peptides function as effective tolerogens, anergizing autoreactive T cells.

Conclusions:

  • Short, non-antigenic peptide tolerogens derived from MBP can effectively treat autoimmune conditions.
  • These peptide-based tolerogens demonstrate significant therapeutic potential for autoimmune diseases like MS.
  • The strategy offers a promising approach for developing safe and effective autoimmune disease therapies.